• Schedule An Appointment
  • (631) 675-5075
  • Career Openings
  • Español 中國傳統的 简体中文
  • Locations
  • Care Team
  • Locations
  • Care Team
    • All Doctors
    • Medical Oncologists
    • Radiation Oncologists
    • Breast Surgeons
    • Surgical Oncologist
    • Support/Palliative
    • Behavioral Health
    • Registered Dietitian Nutritionists
    • Our APPs
  • Patients
    • Accepted Insurance
    • Appointments
    • Blood Disorders
    • Cancers
    • Carespace Portal
    • Fill my Prescription
    • Make A Payment
    • Mammography
    • Medical Marijuana
    • Patient Advocacy
    • Physical Therapy
    • Radiology
  • Professionals
    • Patient Referral
    • Clinical Trials
    • Our Research Center
    • Our Research Team
    • Career Opportunities
    • News & Events
    • NCCN Guidelines
    • Oncology Medical Home (OMH)
  • Research
    • About Research
    • Common Questions
    • Study Participation
    • Our Research Center
    • Our Research Team
    • Clinical Trials
  • About
    • About Us
    • Events
    • News & Updates
    • Our Leadership
    • Our Difference
    • Our Friends
    • Our Services
      • Medical Oncology
      • Radiation Oncology
      • Hematology
      • Fill My Prescription
      • Physical Therapy
      • Health & Wellness
      • Laboratory Testing
      • Personalized Medicine
      • Diagnostic Imaging
      • Other Services
    • Career Opportunities
      • Opportunities
      • Request for Educational Opportunities
    • Newsletters

ASCENT-05: Adjuvant Sacituzumab Govitecan Plus Pembrolizumab for Patients with Triple Negative Breast Cancer

Condition: Breast Cancer

Sponsor: Gilead Sciences, Inc.

Full Title
Protocol GS-US-595-6184: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Study Treatment
Arm A: Anti-TROP2 antibody-drug conjugate sacituzumab govitecan + pembrolizumab
Arm B: pembrolizumab +/- capecitabine

Eligibility/Info
Non-metastatic triple negative breast cancer treated with neoadjuvant systemic therapy followed by surgery.

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology


Go To Trial Homepage

Call Us

(631) 675-5075

Contact us today to request an appointment.

Virtual & Telemedicine available.

Request Appointment

Patient Links

  • Make An Appointment
  • Make A Payment
  • Fill My Prescription
  • Accepted Insurance
  • Medical Marijuana
  • Appointment Information
  • Physical Therapy
  • Patient Advocacy
  • Carespace Portal
  • Cancer Information

About

  • Our Story
  • Our Care Team
  • Locations
  • Careers & Job Openings
  • Newsletters
  • What Is Cancer?
  • What Are Blood Disorders?
  • What Is Oncology?
  • What Is Hematology?
  • Podcasts
  • Oncology Medical Home (OMH)

Research

  • About Research
  • Common Questions
  • Study Participation
  • Our Research Center
  • Our Research Team
  • Clinical Trials
  • Observational Studies
  • Cancer Resources
  • Blood Disorder Resources

Contact Us


info@nycancer.com

  • Terms and Conditions
  • Privacy Policy
  • HIPAA and Compliance
  • Healthix
© 2025 NYCancer.com